Abstract
Nontraditional risk factors for cerebrovascular disease are rapidly emerging. The categories are expanding, and include those related to infection, inflammation, sleep disorders, hemostasis, nutrition, endocrine, and ones individual genotype. Many of the promising factors lack large randomized prospective population studies confirming direct cause and effect. However there have been strong evidence supporting increased stroke risk factor for infection, obstructive sleep disorders, the metabolic syndrome and impaired glucose tolerance in particular. Unique drug targets have already been identified in some of these emerging risk factors. The complexity of the pathophysiology of this disease remains a challenge. For example despite repeated evidence of estrogen-related neuroprotection, large populationbased studies in postmenopausal women receiving estrogen replacement did not demonstrate the expected neuroprotection. This suggests that aggressive research both at the basic science and transitional level needs to evolve, to ensure targeted successful stroke therapy. The advent of nanotechnology including the development of targeted therapeutic nanospheres, and of revolutionary molecular technology resulting in the synthesis of specific peptide mimetics, bodes well for the future development of cerebrovascular drug treatment.
Keywords: Cerebral ischemia, stroke, nontraditional, novel, risk factors, cerebrovascular, obstructive sleep disorder, metabolic syndrome, inflammation, infection
Current Drug Targets
Title: Emerging Risk Factors for Cerebrovascular Disease
Volume: 8 Issue: 7
Author(s): Nina J. Solenski
Affiliation:
Keywords: Cerebral ischemia, stroke, nontraditional, novel, risk factors, cerebrovascular, obstructive sleep disorder, metabolic syndrome, inflammation, infection
Abstract: Nontraditional risk factors for cerebrovascular disease are rapidly emerging. The categories are expanding, and include those related to infection, inflammation, sleep disorders, hemostasis, nutrition, endocrine, and ones individual genotype. Many of the promising factors lack large randomized prospective population studies confirming direct cause and effect. However there have been strong evidence supporting increased stroke risk factor for infection, obstructive sleep disorders, the metabolic syndrome and impaired glucose tolerance in particular. Unique drug targets have already been identified in some of these emerging risk factors. The complexity of the pathophysiology of this disease remains a challenge. For example despite repeated evidence of estrogen-related neuroprotection, large populationbased studies in postmenopausal women receiving estrogen replacement did not demonstrate the expected neuroprotection. This suggests that aggressive research both at the basic science and transitional level needs to evolve, to ensure targeted successful stroke therapy. The advent of nanotechnology including the development of targeted therapeutic nanospheres, and of revolutionary molecular technology resulting in the synthesis of specific peptide mimetics, bodes well for the future development of cerebrovascular drug treatment.
Export Options
About this article
Cite this article as:
Nina J. Solenski , Emerging Risk Factors for Cerebrovascular Disease, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077364
DOI https://dx.doi.org/10.2174/138945007781077364 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade
Endocrine, Metabolic & Immune Disorders - Drug Targets Peripartum Cardiomyopathy: An Intensivist's Perspective
Current Women`s Health Reviews Intravital Microscopy Imaging Approaches for Image-Guided Drug Delivery Systems
Current Drug Targets Diabetic Theory in Anti-Alzheimer’s Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors
Current Medicinal Chemistry The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications
Current Gene Therapy Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design The Role of Platelets in Bone Remodeling
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacogenomic Considerations in the Treatment of the Pediatric Cardiomyopathy Called Barth Syndrome
Recent Patents on Biotechnology Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research Leptin and Inflammation
Current Immunology Reviews (Discontinued) Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry Impacts of Particulate Air Pollution on Asthma: Current Understanding and Future Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery